1. Home /
    2. Altai Protocol Library /
  2. New Indication: Adjuvant atezolizumab + bevacizumab in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Search Library Posts Search
Altai Protocol Library

New Indication: Adjuvant atezolizumab + bevacizumab in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence

New Indication: Adjuvant atezolizumab + bevacizumab in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence
Study:
  • Phase III, randomized, controlled, multicenter, open-label trial (İMbrave050)
  • HCC pts at high risk of recurrence following resection or ablation.
  • Atezolizumab + Bevacizumab q21 for 1 year or 17 cycles (n=334) vs. active surveillance (n=334)
Efficacy:
  • 12 month Independent review facility-assessed recurrence-free survival (IRF-RFS): 78% (95% CI, 73%-82%) and 65%; RFS: NR vs. NR, HR:0.72 [0.56-0.93], p=0.012
Safety:
  • Grade≥3 AEs: Hypertension (15.2% vs 1%), AST increase (7.0% vs 0%)

Journal of Clin Oncol 2023 41:16_suppl, 4002-4002

Kudo M et al. Efficacy, safety and patient reported outcomes (PROs) from the phase III IMbrave050 trial of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation.

http://doi.org/10.1200/JCO.2023.41.16_suppl.4002

Reviewed by Elvin CHALABİYEV, MD on JUN 10, 2023

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More